Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Leukemia

Trial Information

Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Official Title: Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial

Summary

The main purpose of this study is to see if ofatumumab with methylprednisolone followed by additional treatment with ofatumumab and lenalidomide can help people with Chronic Lymphocytic Leukemia (CLL) get rid of their CLL for a long period of time. Researchers also want to find out if the combination of ofatumumab with methylprednisolone followed by additional treatment with ofatumumab and lenalidomide is safe and tolerable.

Phase: Phase 2

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Locations (1)

Country State City Zip Facility and Contact
United States Florida Tampa 33612 H. Lee Moffitt Cancer Center and Research Institute
Elyce Turba, RN
813-745-1706
elyce.turba@moffitt.org

Celeste Bello, M.D.
Principal Investigator

Jeffrey Lancet, M.D.
Sub-Investigator

Lubomir Sokol, M.D., Ph.D.
Sub-Investigator

Javier Pinilla-Ibarz, M.D., Ph.D.
Sub-Investigator

Eduardo Sotomayor, M.D.
Sub-Investigator

Bijal Shah, M.D.
Sub-Investigator

NCT ID:NCT01496976

Date Last Changed: April 26, 2013